Suppr超能文献

根治性(化疗)放疗治疗颈段食管鳞状细胞癌的肿瘤学结局:一项系统评价和荟萃分析

Oncological outcomes of squamous cell carcinoma of the cervical esophagus treated with definitive (chemo-)radiotherapy: a systematic review and meta-analysis.

作者信息

De Virgilio Armando, Costantino Andrea, Festa Bianca Maria, Mercante Giuseppe, Franceschini Davide, Franzese Ciro, Scorsetti Marta, Marrari Andrea, Cavina Raffaele, Marano Salvatore, Castoro Carlo, Spriano Giuseppe

机构信息

Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090, Pieve Emanuele, Milan, Italy.

Otorhinolaryngology Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089, Rozzano, Milan, Italy.

出版信息

J Cancer Res Clin Oncol. 2023 Mar;149(3):1029-1041. doi: 10.1007/s00432-022-03965-8. Epub 2022 Mar 2.

Abstract

PURPOSE

To determine the oncological outcomes of cervical esophageal squamous cell carcinoma (CESCC) treated with definitive chemoradiotherapy (CRT).

METHODS

A systematic review and meta-analysis was performed according to the PRISMA guidelines.

RESULTS

A total of 1222 patients (median age: 63.0 years, 95% CI 61.0-65.0) were included from 22 studies. The median follow-up time was 34.0 months (n = 1181, 95% CI 26.4-36.0). Estimated pooled OS rates (95% CI) at 1, 3, and 5 years were 77.9% (73.9-82.2), 48.4% (43.2-54.3), and 35.3% (29.7-41.9), respectively. The median OS (95% CI) was 33.4 months (25.8-42.2). Estimated pooled PFS rates (n = 595; 95% CI) at 1, 3, and 5 years were 64.1% (57.9-71.0), 38.0% (33.3-45.5), and 29.8% (23.9-37.1), respectively. The median PFS (95% CI) was 19.8 months (14.9-26.6).

CONCLUSIONS

Definitive CRT is a valuable first-line treatment for the management of CESCC. Further studies should focus on survival predictors able to define stage-based clinical guidelines.

摘要

目的

确定接受根治性放化疗(CRT)的颈段食管鳞状细胞癌(CESCC)的肿瘤学结局。

方法

根据PRISMA指南进行系统评价和荟萃分析。

结果

纳入了来自22项研究的总共1222例患者(中位年龄:63.0岁,95%CI 61.0 - 65.0)。中位随访时间为34.0个月(n = 1181,95%CI 26.4 - 36.0)。1年、3年和5年的估计总生存(OS)率(95%CI)分别为77.9%(73.9 - 82.2)、48.4%(43.2 - 54.3)和35.3%(29.7 - 41.9)。中位OS(95%CI)为33.4个月(25.8 - 42.2)。1年、3年和5年的估计无进展生存(PFS)率(n = 595;95%CI)分别为64.1%(57.9 - 71.0)、38.0%(33.3 - 45.5)和29.8%(23.9 - 37.1)。中位PFS(95%CI)为19.8个月(14.9 - 26.6)。

结论

根治性CRT是CESCC治疗中有价值的一线治疗方法。进一步的研究应聚焦于能够定义基于分期的临床指南的生存预测因素。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验